A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.

@article{Zang2017ART,
  title={A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.},
  author={Yong Zang and J Jack Lee},
  journal={Statistics in medicine},
  year={2017},
  volume={36 1},
  pages={
          27-42
        }
}
We propose a robust two-stage design to identify the optimal biological dose for phase I/II clinical trials evaluating both toxicity and efficacy outcomes. In the first stage of dose finding, we use the Bayesian model averaging continual reassessment method to monitor the toxicity outcomes and adopt an isotonic regression method based on the efficacy outcomes to guide dose escalation. When the first stage ends, we use the Dirichlet-multinomial distribution to jointly model the toxicity and… CONTINUE READING

Figures and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Evaluating the performance of copula models in phase I–II clinical trials under model misspecification

K Cunana, JK Koopmeiners
  • BMC Medical Research Methodology
  • 2014
VIEW 1 EXCERPT

Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011
VIEW 3 EXCERPTS

An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010